Table 1.
Characteristics of the patients with HCC according to Sorafenib response
| Disease control (n = 26) | Disease progression (n = 37) | Univariate, P value | Multivariate, P value; OR (95% CI) | |
|---|---|---|---|---|
| Age, year | 51.5 ± 7.5 | 49.6 ± 8.3 | 0.37 | |
| Gender (male/female) | 22/4 | 33/4 | 0.71 | |
| Underlying liver disease, no (%) | ||||
| HBV | 22 (84.6%) | 31 (83,8%) | ||
| HCV | 1 (3.8%) | 2 (5.4%) | ||
| Chronic alcoholism | 3 (11.5%) | 3 (8.1%) | ||
| Autoimmune hepatitis | 0 (%) | 1 (2.7%) | 0.92 | |
| Child‐Pugh score, (A/B) | 23/3 | 31/6 | 0.73 | |
| BCLC staging, (B/C) | 12/14 | 5/32 | 0.008** | 0.022*; 3.92 [1.31‐12.86] |
| AFP > 400 ng/ml, no (%) | 12 (46.2%) | 21 (56.8%) | 0.45 | |
| Diameter of largest tumor > 3 cm, no (%) | 17 (65.4%) | 30 (81.1%) | 0.24 | |
| Tumor number > 5, no (%) | 13 (50%) | 26 (70.3%) | 0.12 | |
| PVTT, no (%) | 1 (3.8%) | 8 (21.6) | 0.07 | |
| Extrahepatic metastasis, no (%) | 6 (22.2%) | 19 (51.4%) | 0.036* | 0.573; 1.47 [0.41‐5.73] |
| High PI16 expression, no (%) | 10 (38.5%) | 26 (70.3%) | 0.019** | 0.037*; 2.83 [1.16‐11.49] |
AFP, alphafetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; OR: odds ratio; CI: confidence interval.
The significance of bold values are shown as follows: *P < .05, **P < .01.